Skip to content

Study · Systematic review · n = 22,096 · 2022

5 results

Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.

Wang F, Mao Y, Wang H, Liu Y, Huang P

Clinical drug investigation11 Dec 2021Cited by 49 (Europe PMC)

PMID34894326 (opens in a new tab)DOI10.1007/s40261-021-01110-w (opens in a new tab)PepBankPUB-34894326
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, semaglutide was not associated with increased diabetic retinopathy risk compared with controls when all trials were combined.

    In plain wordsIn adults with type 2 diabetes, semaglutide was not linked to more diabetic retinopathy than control treatment across all trials combined.

    Peptide
    Semaglutide
    Outcome
    No significant changeDiabetic retinopathy risk, all trials combined
    Study

    n = 22,096

    Comparator
    Control
    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    RR
    1.14 ratio
    all trials combined
    95% CI
    0.98 to 1.33 ratio
    all trials combined

    Source sentences

    Summary
    Overall, semaglutide was not associated with increased DR risk compared with controls when all trials were combined (RR 1.14, 95% CI 0.98-1.33).
    2 context sentences
    Summary · context
    Electronic databases were systematically searched up to April 2021 to identify randomized controlled trials that reported diabetic retinopathy (DR) events in semaglutide-treated and control groups.
    Summary · context
    A total of 23 randomized trials involving 22,096 patients with T2DM were included.
  2. 02HumanSystematic reviewSafety outcome

    Across the included trials, 463 incident diabetic retinopathy cases occurred in the semaglutide group and 267 in the control group.

    In plain wordsAcross the trials, 463 cases of diabetic retinopathy occurred in the semaglutide group and 267 in the control group.

    Peptide
    Semaglutide
    Outcome
    Not applicableIncident diabetic retinopathy cases
    Study

    n = 22,096

    Comparator
    Control
    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    Diabetic retinopathy cases
    463 cases
    semaglutide group
    Diabetic retinopathy cases
    267 cases
    control group

    Source sentences

    Summary
    There were 730 incident DR cases-463 in the semaglutide group and 267 in the control group.
    2 context sentences
    Summary · context
    Electronic databases were systematically searched up to April 2021 to identify randomized controlled trials that reported diabetic retinopathy (DR) events in semaglutide-treated and control groups.
    Summary · context
    A total of 23 randomized trials involving 22,096 patients with T2DM were included.
  3. 03HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, semaglutide was associated with an increased risk of diabetic retinopathy compared with placebo in a subgroup analysis.

    In plain wordsIn adults with type 2 diabetes, semaglutide was linked to more diabetic retinopathy than placebo in a subgroup analysis.

    Peptide
    Semaglutide
    Outcome
    IncreaseDiabetic retinopathy risk, semaglutide vs placebo subgroup
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    RR
    1.24 ratio
    semaglutide vs placebo
    95% CI
    1.03 to 1.5 ratio
    semaglutide vs placebo

    Source sentences

    Summary
    Subgroup analysis showed that semaglutide was associated with an increased risk of DR compared with placebo (RR 1.24, 95% CI 1.03-1.50).
    2 context sentences
    Summary · context
    Electronic databases were systematically searched up to April 2021 to identify randomized controlled trials that reported diabetic retinopathy (DR) events in semaglutide-treated and control groups.
    Summary · context
    A total of 23 randomized trials involving 22,096 patients with T2DM were included.
  4. 04HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, patient age of 60 years or more was a factor for increased risk of diabetic retinopathy when using semaglutide.

    In plain wordsIn adults with type 2 diabetes aged 60 or older, semaglutide was linked to a higher risk of diabetic retinopathy.

    Peptide
    Semaglutide
    Outcome
    IncreaseDiabetic retinopathy risk, age 60 years or older
    Study

    n: not reported in source

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    RR
    1.27 ratio
    age >=60 years
    95% CI
    1.02 to 1.59 ratio
    age >=60 years

    Source sentences

    Summary
    patient age ≥ 60 years and diabetes duration ≥ 10 years were also factors for increased risk of DR when using semaglutide (RR 1.27, 95% CI 1.02-1.59
    2 context sentences
    Summary · context
    Electronic databases were systematically searched up to April 2021 to identify randomized controlled trials that reported diabetic retinopathy (DR) events in semaglutide-treated and control groups.
    Summary · context
    A total of 23 randomized trials involving 22,096 patients with T2DM were included.
  5. 05HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, diabetes duration of 10 years or more was a factor for increased risk of diabetic retinopathy when using semaglutide.

    In plain wordsIn adults with type 2 diabetes for 10 years or longer, semaglutide was linked to a higher risk of diabetic retinopathy.

    Peptide
    Semaglutide
    Outcome
    IncreaseDiabetic retinopathy risk, diabetes duration 10 years or longer
    Study

    n: not reported in source

    Outcome group
    Adverse events · Eye
    Studied dose
    Dose not stated

    Measurements

    RR
    1.28 ratio
    diabetes duration >=10 years
    95% CI
    1.04 to 1.58 ratio
    diabetes duration >=10 years

    Source sentences

    Summary
    patient age ≥ 60 years and diabetes duration ≥ 10 years were also factors for increased risk of DR when using semaglutide (RR 1.27, 95% CI 1.02-1.59; RR 1.28, 95% CI 1.04-1.58
    2 context sentences
    Summary · context
    Electronic databases were systematically searched up to April 2021 to identify randomized controlled trials that reported diabetic retinopathy (DR) events in semaglutide-treated and control groups.
    Summary · context
    A total of 23 randomized trials involving 22,096 patients with T2DM were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.